Background and Aims: Fibrosis is a common complication of Crohn's disease [CD], and is related to dysregulated tissular repair following inflammation, in which macrophages play a central role. We have previously observed that STAT6 −/− mice present delayed mucosal recovery after 2,4,6-trinitrobenzenesulfonic acid [TNBS]-induced colitis due to a deficiency in reparatory interleukin-4 [IL4]/STAT6-dependent M2 macrophages, which can be reverted by the exogenous transfer of this cell type. In the present study, we analyse the role of STAT6-dependent macrophages in intestinal fibrosis. −/− animals. Instead, the latter group showed an increase in CD16 + macrophages that correlated with the expression of fibrogenic markers. CD16 + macrophages were also increased in the damaged mucosa of Crohn's disease patients with stenotic or penetrating complications. Finally, administration of IL4-treated WT macrophages to STAT6 −/− mice reduced TNBS-induced fibrosis. Conclusions: Our study demonstrates that STAT6 deficiency dysregulates the macrophage response to inflammatory outbursts by increasing the presence of a population of CD16 + macrophages that seems to contribute to intestinal fibrosis.
Introduction
Crohn's disease [CD] patients often present intestinal fibrosis as a complication of chronic inflammation. The consequent architectural distortion provokes intestinal narrowing and obstruction that requires surgery in over one-third of these patients, and so fibrosis is increasingly recognized as a major cause of morbidity and mortality. No treatment strategies are currently available; thus, a better understanding of the cellular and molecular mechanisms that underlie its pathogenesis is urgently needed.
Fibrosis is a consequence of dysregulated tissular repair following inflammation. In general, adequate healing after tissue injury relies on mesenchymal cells acting under the influence of elements of the immune system, especially macrophages. In normal conditions, macrophages, after contributing to the inflammatory reaction, change their phenotype to limit inflammation and promote tissular repair. 1 This functional plasticity depends on their adaptation to environmental changes that provoke a reprogramming of their gene expression, particularly regulated by the STAT family of transcription factors. While the initial Th1 pro-inflammatory cytokines and bacterial products activate STAT1 signalling to generate proinflammatory or M1 macrophages, the appearance of apoptotic neutrophils marks a shift towards the M2 reparatory and pro-resolving profiles, which depend mainly on the sequential activation of STAT6 and STAT3 in response to interleukin [IL] 4/IL13 and IL10, respectively. 2 In chronic conditions, this sequence is interrupted, macrophages accumulate in the inflamed tissue and macrophages that normally repair the tissue promote fibrosis. Indeed, a contributing role to fibrosis for persistent IL4-dependent macrophages has been demonstrated in the pancreas, 3 lung 4 and kidney, 5 and antibodies against this cytokine are being tested to reduce pulmonary fibrosis. 6 The contribution of macrophages to fibrosis in the gastrointestinal tract is poorly studied, although there is evidence to suggest a differential response in intestine vs the above-mentioned tissues. For example, the profibrogenic M2-polarizing cytokine IL13 does not seem to play a role in fibrostenotic CD, 7, 8 and IL4-stimulated macrophages do not appear to be pro-fibrotic in this setting. 9 These particularities may be related to specific characteristics of the intestinal wall. First, its integrity depends on continuous and rapid epithelial renewal, 10 which endows this territory with a significant potential for mucosal repair. Second, the intestinal epithelial barrier separates the mesenchymal compartment from the abundant luminal microbiota that stimulate its activation. 11 Thus, in this territory, mucosal restitution after each inflammatory flare may be particularly important. We have previously observed that STAT6 −/− mice present a delayed wound-healing after 2,4,6-trinitrobenzenesulfonic acid [TNBS]-induced colitis due to their inability to generate STAT6-dependent M2 macrophages, and found that administration of this cell type exerted a protective effect. 12 However, we also detected that M2 macrophages identified by the expression of the most commonly used marker, CD206, accumulate with chronicity in inflammation bowel disease [IBD] patients. 13, 14 The significance of this latter observation is naturally limited by the fact that the detected macrophages may include various phenotypic subtypes that serve different purposes. 15 In the present study we analyse the role of STAT6-dependent macrophages in intestinal fibrosis. 
Methods

Induction of chronic colonic inflammation and fibrosis WT and STAT6
−/− mice received a weekly intra-rectal administration of a solution of TNBS [Sigma Aldrich] or 0.9% saline during 6 weeks according to the method previously reported. 16 The weekly dose of TNBS was progressively increased [weeks 1 and 2: 0.5 mg TNBS in 30% ethanol; weeks 3 and 4: 0.75 mg TNBS in 45% ethanol; weeks 5 and 6: 1.0 mg TNBS in 45% ethanol]. Administration was performed under light anaesthesia via a medical-grade polyurethane tube [diameter, 1 mm] carefully inserted through the anus into the colon. The catheter was introduced 3 cm from the anus and a total volume of 100 µl was delivered. Mice were then hung upside down for 1 min. On a daily basis, animals were weighed, monitored for food and fluid intake and examined for signs of colitis including weight loss, diarrhoea, rectal bleeding and prolapse, as well as signs of systemic inflammation, such as piloerection, lethargy and periorbital exudates. Animals were killed by cervical dislocation 7 days after the second, fourth and sixth doses [days 14, 28 and 42], and their colons excised. Colonic tissue was frozen in liquid nitrogen for protein and RNA extraction, fixed in 4% paraformaldehyde and embedded in paraffin for histological analysis, or used to obtain lamina propria macrophages.
Human intestinal mucosal samples
Colonic surgical resections were obtained from CD patients undergoing surgery because of stenotic or penetrating complications and from colon cancer patients [ Table 1 ]. Analyses were performed in the damaged mucosa of CD patients and the unaffected tissue portion from cancer resections. The study was approved by the Institutional Review Board of The Hospital of Manises [Valencia] . Written informed consent was obtained from all patients.
Isolation of murine peritoneal macrophages and in vitro polarization
WT and STAT6
−/− mice were killed by cervical dislocation and 10 ml of cold PBS was injected into the peritoneal cavity. The fluid was then withdrawn and centrifuged for 5 min at 350 g at 4°C. The pellet was re-suspended in RPMI-1640 [HiClone, GE Healthcare Life Science] and supplemented with 2% penicillin-streptomycin and 10% fetal bovine serum [FBS] , and cells were seeded in Petri dishes for 4 h at 37°C. Non-adherent cells were subsequently removed by washing with PBS and adherent macrophages were polarized toward the M2a phenotype by 72-h treatment with IL4 [20 ng/ml], as previously described. 
Results
STAT6 deficiency favours fibrosis in a chronic murine model of colitis
WT and STAT6 −/− mice receiving a weekly intrarectal administration of TNBS suffered an increase in mortality compared with vehicletreated animals, but this difference only reached statistical significance in the latter group [ Figure 1a] . A transient loss of body weight was observed 2-3 days after each TNBS enema, with the variation being more pronounced again among the STAT6 −/− mice [ Figure 1b ]. Colonic sections analysed 7 days after the last TNBS dose exhibited intense inflammation and increased thickness of the wall. Trichrome staining of connective tissue revealed that chronic administration of TNBS to WT mice did not affect collagen deposition. Vehicle-treated STAT6 −/− mice presented a wider band of collagen fibres that was slightly increased and reached statistical significance when the animals were treated with TNBS [ Figure 1c , d]. The increase in collagen deposition was mainly observed in the subepithelial space, resembling the histological characteristics of collagenous colitis.
To further characterize the fibrogenic process, we analysed the gene expression for collagen [Col1a1], for enzymes involved in tissue destruction and remodelling, such as MMP-2 and TIMP-1, and for STAT3, a transcription factor with significance for both healing and fibrosis. Additionally The expression of some of these markers was slightly elevated in STAT6 −/− mice, and TNBS provoked a significant increase in mRNA levels for Col1a1, MMP2, TIMP1, vimentin and αSMA in these mice but not in WT animals. E-cadherin mRNA levels were similar in all groups [ Figure 1e ].
Together, the results suggest that STAT6 −/− mice are more vulnerable to developing intestinal fibrosis as a result of repeated inflammatory insults with TNBS.
STAT6 deficiency diminishes CD206
+ and increases CD16 + macrophages in the mucosa of TNBS-treated mice Mucosal macrophages defined as F4/80 + cells were isolated by means of the Mini MACS separator 7 days after the second, fourth and sixth administration of TNBS or vehicle and were analysed by flow cytometry. The cellular population obtained by this procedure was 89.3 ± 1.7% positive for F4/80 as measured by flow cytometry.
The percentage of CD86-positive cells was higher in TNBStreated WT and STAT6 −/− mice than in the respective vehicle-treated groups at day 14. The percentage of CD206 + cells was significantly increased at days 14 and 28 in WT TNBS-treated mice, while it remained at basal levels in STAT6 −/− TNBS-treated animals. In contrast, the percentage of CD16 + macrophages was significantly higher in STAT6 −/− mice receiving TNBS than in any other experimental group at any time analysed [ Figure 2a ].
The expression of CD16 showed a positive and significant correlation with that of the fibrosis indicators that were specifically increased by TNBS in STAT6 −/− mice [vimentin, αSMA, MMP-2, Figure 2b ].
CD patients present increased levels of CD16 + macrophages
Cellular populations isolated from control colonic tissues and CD-affected mucosa were analysed by flow cytometry to detect lamina propria macrophages as CD45 + CD14 + CD64 + cells, which were further characterized by their positivity for CD86, CD206, CD16 and CD163. Around 8% of lamina propria macrophages were positive for the M1 marker CD86 in control tissues, and this proportion was significantly higher in the damaged mucosa of CD patients. In contrast, most intestinal macrophages were positive for CD206 and CD163, and no differences were observed between control and CD samples. Finally, CD16
+ macrophages were mostly included in the group of CD206 + cells and the percentage was significantly higher in CD patients than in control subjects [ Figure 2c ]. Figure 3b ]. The contribution of macrophages to the expression of Wnt ligands in the mucosa was further analysed by RT-PCR in macrophages isolated from the mucosa at the end of the 8-week experimental period according to their positivity for CD16. These macrophages showed increased expression of STAT3 and Wnt6 when isolated from TNBStreated STAT6-deficient mice, but not when they came from WT animals [ Figure 3c ]. 
Administration of IL4-treated WT macrophages to STAT6
−/− mice reduces fibrosis Peritoneal murine macrophages were obtained from WT and STAT6 −/− mice and polarized into M2a macrophages in vitro by incubation with IL4, which provoked an increase in the mRNA expression of Wnt2b and Wnt10a in WT macrophages but not in STAT6-deficient cells. No significant change was observed between the two populations with regard to Wnt6 expression [ Figure 4a ].
These macrophages were administered intraperitoneally to STAT6 −/− mice 2 days after each TNBS dose to reproduce the response observed in WT animals after TNBS administration. 12 As shown in Figure 4b , the rate of mortality was reduced in mice receiving exogenous macrophages compared to that observed in STAT6-deficient mice receiving only TNBS, but the protection only reached statistical significance when the administered macrophages were from WT donors. In parallel, mice receiving WT macrophages had higher body weights throughout the experimental period but without reaching statistical significance [ Figure 4c ]. These STAT6-deficient mice treated with IL4-treated WT macrophages showed reduced mRNA expression of the fibrotic markers vimentin, αSMA and MMP2, while the expression of CD16 was significantly reduced in the two subgroups of recipient mice [ Figure 4d ]. Together, these results suggest that administration of M2a macrophages, which signal through STAT6 and accelerate mucosal repair in TNBS-treated STAT6 −/− mice via activation of the Wnt signalling pathway, 12 prevent the development of fibrosis.
Discussion
The present study demonstrates that a lack of the transcription factor STAT6 leads to a predisposition to fibrosis in a murine model of colonic inflammation. STAT6 −/− mice exhibit constitutively increased expression of some fibrosis markers and tend to present thicker mesenchymal tissue in the colonic mucosa, characteristics that are enhanced by a regime of TNBS that fails to affect mucosal structure in WT animals. This predisposition is associated with an altered macrophage response that seems to disturb mucosal repair after acute insults and which can be reversed with the exogenous administration of macrophages with a STAT6-dependent phenotype.
WT mice displayed elevated levels of CD206 + macrophages throughout the experimental period, while normal levels of these cells were observed in STAT6 −/− animals. WT mice probably increase CD206 + macrophages because each TNBS insult triggers a macrophage response that is fundamental for mucosal recovery. 12 In fact, the exogenous administration of WT IL4-treated macrophages to our STAT6 −/− mice after each TNBS dose significantly reduced the fibrotic response. These results suggest that the absence of STAT6 and the consequent inability to generate the reparatory macrophage phenotype that depends on the IL4/IL13-STAT6 signalling pathway underlies the origin of fibrosis [ Figure 5 ].
On the other hand, STAT6 −/− mice presented a progressive accumulation of CD16 + macrophages and the expression of CD16 correlated with that of fibrotic markers in this group, but not in WT mice. This suggests that this subgroup of macrophages contributes to fibrosis and, accordingly, the protection elicited by exogenous macrophages is accompanied by a reduced expression of CD16 in the mucosa. Most relevant is the significant increase in CD16 + macrophages revealed by our analysis of macrophage infiltration in intestinal samples obtained from IBD patients undergoing surgery because of stenotic or penetrating complications. Thus, although TNBS-treated STAT6 −/− mice showed a mild fibrosis in the submucosal space and not the transmural lesions characteristics of CD, the pattern of macrophage infiltration resembles that present in fibrotic samples obtained from this group of patients. Previous studies have shown that levels of CD16 + circulating monocytes and mucosa-infiltrating cells increase with disease activity. [23] [24] [25] We can now substantiate their contribution to fibrosis in agreement with in vitro evidence of CD16 up-regulation in response to TGFβ 26, 27 and previous reports indicating that CD16 + monocytes and macrophages contribute to fibrosis in the liver and skin. [27] [28] [29] Thus, a lack of STAT6-dependent macrophages has two consequences-deficient healing and the accumulation of CD16 + macrophages-both of which promote fibrosis. The role of IL4-stimulated macrophages in tissue repair is evident in different organs, 12, 18, 19 but their function requires in-depth
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study, as there is evidence that they also contribute to fibrosis. In contrast to the tendency towards intestinal fibrosis observed in STAT6 −/− mice, deletion of IL4 receptor-α or IL4 co-stimulators has been reported to protect against fibrosis in the skin, 19 mesentery 18 and pancreas. 3 We cannot rule out that these differences are related to tissular particularities, as in the recently described case of IL4 signalling enhancers, 19 or with additional effects derived from impeding STAT6 transcription activity regulated by other mediators. However, a wider range of effects would be expected following deletion of the IL4 receptor-α itself rather than deletion of one, albeit significant, of its downstream signalling pathways [i.e. STAT6]. 20 For example, deletion of the IL4 receptor-α would impede IL4 and IL13 stimulation of STAT3, 21, 22 which is likely to influence macrophage phenotype. In fact, we have observed that reduction in STAT6-dependent macrophages is associated with up-regulation of STAT3 in the intestinal mucosa and that the CD16 + macrophages that accumulate in these circumstances display increased STAT3 expression. Therefore, it appears that the absence of STAT6-mediated signalling permits activation of STAT3-dependent macrophages.
Macrophages are the source of many mediators with profibrotic activities, among which TGFβ is the most prominent. In fact, STAT6 −/− mice present higher levels of TGFβ mRNA, and its expression correlates with that of CD16. However, TNBS does not increase its expression, and correlation with the macrophage marker occurs in WT and STAT6 −/− mice, which suggests that TGFβ is not responsible for the differential response observed in the latter group. Macrophages are also a source of Wnt ligands, which play a central role in promoting the growth of cells aimed at repairing tissue after mucosal damage. 10 We have previously observed that macrophages secrete Wnt2b, Wnt7 and Wnt10a in a STAT6-dependent manner and that a deficit of these ligands in STAT6 −/− mice undermines acute wound repair. 12 Interestingly, a recent study assigns a particularly essential role to Wnt2b secreted from extra-epithelial sources in intestinal epithelial renewal, 30 while a reduced production of this mediator has been observed in fibroblasts isolated from stenotic CD patients. 31 Thus, the beneficial effect of administering IL4-stimulated WT macrophages after each TNBS gavage is probably mediated by the increased supply of Wnt ligands that accompanies it. However, the mucosa of our STAT6 −/− mice displayed augmented levels of Wnt6 and Wnt10a mRNA at the end of the experimental period, and Wnt6 expression correlated with that of macrophage markers and was higher in CD16 + macrophages. These results, together with the observed increase in Wnt signalling, suggest that Wnt6 contributes to fibrosis. In this way, Wnt ligands as a whole appear to be a double-edged sword with respect to mucosal injury, since they affect both healing and fibrosis. This concept has already been demonstrated in the kidney, 32 and calls for further exploration of their functions with the hope of finding specific roles for specific ligands to deduce the therapeutic value of modulating their function.
In summary, the present study demonstrates that deficiencies in STAT6 activity dysregulate the macrophage response to inflammatory flares by increasing the presence of a population of CD16 + macrophages associated with enhanced susceptibility to intestinal fibrosis. Better knowledge of the particular roles played by macrophages in intestinal fibrosis would help to define potential cellular approaches to IBD therapy.
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